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Summary Using zymography and computer assisted image analysis, we have measured the levels of type IV
collagenases in biopsies from normal breast, and benign and malignant breast disease. The 92 kDa form was
present in three of 11 cases of normal/benign disease, three of nine grade I tumours, four of 12 grade II
tumours, but 11 of 11 grade III tumours. Mean levels were higher in grade III tumours (P<0.0001). When
the levels of 72 kDa collagenase and its active 62 kDa form were considered together, there was no difference
between the benign and malignant cases (P = 0.55), but the amount of active enzyme, considered as a
proportion of the 62 + 72 kDa forms, was significantly higher in malignant disease (P = 0.003). There was also
a trend towards a higher proportion of active enzyme with increasing tumour grade (P<0.0001). In situ
hybridisation and immunohistochemistry studies showed that that mRNA and protein for the 92 kDa enzyme
was primarily found in the tumour stroma. mRNA for the 72 kDa enzyme was also found in stromal areas.
This study demonstrates a clear relationship between production ofType IV collagenases and malignant breast
disease. Inhibitors of these enzymes may be of value in preventing metastatic disease.
In normal glandular tissue a specialised form of extracellular
matrix, the basement membrane, separates epithelial cells
from the underyling stroma. In benign breast disease and
carcinoma in situ, basement membrane is preserved, but is
partially or completely lost in invasive carcinoma of the
breast (Siegel et al., 1981). Basement membrane contains
laminin, heparan sulphate proteoglycan and type IV collagen
and other extracellular matrix components. The degradation
of type IV collagen may be a prerequisite for metastasis
formation.
Matrix metalloproteases are a family ofhighly homologous
proteolytic enzymes involved degradation of basement mem-
brane. Each member has a different substrate specificity.
Matrix metalloprotease-l (MMP-1) degrades interstitial col-
lagen, stromelysin (MMP-3) degrades proteoglycans, whilst
the two type IV collagenases of molecular weights 72 kDa
(MMP-2) and 92 kDa (MMP-9) are capable of degrading
type IV collagen, gelatin and fibronectin (Liotta & Stetler-
Stevenson, 1991). Type IV collagenases are secreted in an
inactive proenzyme form and activation results from the
removal of an 80 amino acid sequence from the N-terminus
(Stetler-Stevenson et al., 1989). This can be achieved in vitro
by treatment with trypsin or organomercurials but the precise
sequence of events required for activation in vivo is unknown.
Matrix metalloproteinases and other proteolytic enzymes
such as cathepsins and plasminogen activating factors may be
involved (Yagel et al., 1989; Goldberg et al., 1990; Ward et
al., 1991).
There is much experimental evidence linking type IV col-
lagenase expression with the metastatic phenotype. Increasing
tumour cell secretion of type IV collagenase by transfecting
with oncogenes, or by clonal selection, enhances their metas-
tic behaviour in experimental animals and their ability to
invade a reconstituted basement membrane in vitro (Garbisa
et al., 1987, 1988). Similarly, decreasing type IV collagenase
activity by tissue inhibitor ofmetalloprotease, TIMP, reduces
the metastatic capacity of tumour cells in animal models
(Alvarez et al., 1990; DeClerk et al., 1992).
Several recent studies have reported type IV collagenases
in human tumour biopsies. The 72 kDa enzyme was found in
neoplastic, but not normal, colonic epithelia by immuno-
histochemical methods (Levy et al., 1991). Pyke et al. (1992),
demonstrated expression of mRNA for the 72 kDa enzyme
by fibroblasts adjacent to tumour cell islands in basal and
squamous cell carincoma, but found no expression in the
tumour cells. This same study demonstrated mRNA for the
92 kDa enzyme by macrophages and some tumour cells in
skin tumours, but not in normal skin. Previous studies of
type IV collagenase expression in human breast neoplasms
have been restricted to immunohistochemical studies using
polyclonal (Daidone et al., 1991; Monteagudo et al., 1990)
antisera to the 72 kDa type IV collagenase. These studies
demonstrated that 72 kDa type IV collagenase was expressed
in both normal and malignant breast biopsies, chiefly by the
myoepithelial cells (Daidone et al., 1991; Monteagudo et al.,
1990). The disadvantage of immunohistochemistry is that
while it gives useful information concerning the localisation
of enzymes, levels cannot be accurately quantified. It has not
been possible to distinguish between the inactive pro-enzyme
and the activated type IV collagenase. Collagenolytic assays
are insensitive and require large amounts of tissue. Addi-
tionally they cannot detect inactive proforms of metallo-
proteinases. The presence of tissue inhibitors of matrix
metaloproteinases (TIMPS) further complicate interpretation
of results.
In this study, we have used zymography (gel substrate
analysis) to investigate the levels of type IV collagenases in
breast tumours. In this technique, small fragments of
homogenised tissue are loaded onto polyacrylamide gels im-
pregnated with gelatin. Collagenase present in the tissue
digests the gelatin, leaving a clear band after the gel is
stained for protein. Zymography can distinguish between the
92 and 72 kDa enzymes and can also distinguish between
inactive and active forms of the 72 kDa enzyme, because
SDS causes enzyme activation (Birkedal-Hansen & Taylor,
1982). The 72 kDa enzyme appears on the zymogram as a
band of apparent molecular weight 72 kDa (inactive precur-
sor) with a doublet beneath this of molecular weight 59/
62 kDa (activated enzyme with inhibitory N-terminal
sequence removed). The active 81 kDa form of the 92 kDa
enzyme is not resolved on the gels and the enzyme appears as
a single band. With computer assisted image analysis, zymo-
graphy can be used as a quantitative analytical method.
Combined with quantitative analysis of active and inactive
type IV collagenases in benign and malignant breast disease,
we have localised the RNA for the 92 and 72 kDa col-
lagenases using in situ hybridisation. We have also localised
the 92 kDa protein using immunohistochemistry.
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Methods
Tissue samples
Breast tissue removed at excision biopsy or mastectomy for
breast disease was cryopreserved in liquid nitrogen. Three
cases of normal breast tissue, eight of benign breast disease,
and 32 of invasive carcinoma of varying histological grade
were examined. Tumour grading was by the modified Bloom-
Richardson classification (Elston, 1984). A 5 gm thick section
was cut from a face area of each tumour. Samples were
homogenised in 501AI of SDS-PAGE sample buffer contain-
ing glycerol (10% v/v) SDS (1% w/v) and bromophenol blue
using treff microhomogenisers (Scott Lab). Adjacent sections
were cut and used for protein estimation, immunohisto-
chemistry and in situ hybridisation. Sections were cut at
varying depths in the block to assess reproducibility of
zymography.
Gelatin zymography
Gelatinolytic zymography was performed as described by
Brown et al., 1990. This technique can distinguish between
the 72 and 92 kDa type IV collagenases. Additionally, the
method can detect the inactive proforms of collagenases
because SDS causes activation of the enzymes without pro-
teolytic cleavage of the inhibitory N-terminal sequence
(Birkedal-Hansen & Taylor, 1982). Homogenised samples
(50pl) were applied directly without heating or reduction to
a 5% w/v stacking polyacrylamide gel laid over an 11%
(w/v) polyacrylamide gel containing 1 mg ml-' gelatin and
0.1% (w/v) SDS. Gels were run at room temp at 180V for
3.5 h. After incubation of gels in 2.5% Triton X-100 for
30 min to remove SDS, the gels were incubated for 16 h at
37°C in 50 mM Tris-HCI, pH 7.6 containing 0.2 M NaCI,
5 mM CaC12 and 0.02 w/v Brij-35. Gels were stained for 3 h
in 30% methanol/10% glacial acetic acid containing 0.5%
(w/v) Coomassie Brilliant Blue G 250 and destained in the
same solution in the absence of dye.
The amount of collagenase present affects not only the
intensity of the band produced but also the size of the band.
Conventional linear densitometric analysis is therefore inade-
quate for assessment of collagenolytic activity. We have used
computer assisted image analysis to overcome this problem.
Images of wet gels were captured using a Sony DXC-1SiP
video camera connected to capture hardware/software
(Screen Machine/SM-camera). NIH Image 1.43 software
equipped with gel plotting macros was used to measure the
integrated density of each band. Conditioned media from
human melanoma RPMI 7951 cells and from TPA stimu-
lated HT1080 fibrosarcoma cells were used as type IV col-
lagenase standards (Brown et al., 1990; Weinberg et al.,
1990). RPMI 7951 constituitively secretes 72 kDa type IV
collagenase and the activity (Lane 1, Figure 1) present in
20iLl of conditioned media (as detected by zymography) was
defined as 100 arbitrary units of type IV procollagenase.
Conditioned media from TPA stimulated HT 1080 fibrosar-
coma cells also contained 72 kDa procollagenase (Lane 2,
Figure 1). In addition to the activated forms of this enzyme
(59 kDa/62 kDa doublet). HT-1080 cells also expressed the
92 kDa type IV collagenase (Lane 1, Figure 1) and the
activity contained in 20jil of conditioned media was defined
as 100 arbitrary units of this enzyme. The resolution of 11%
acrylamide gels is insufficient to distinguish between the pro-
form of 92 kDa type IV collagenase and its 81 kDa activated
form.
Protein estimation
Single 5 ym cryostat sections from each tumour were
homogenised in 1% (w/v) SDS and diluted 10-fold in water
before measuring protein content against bovine serum
albumin using a Bio-Rad protein assay reagent (Bradford,
1976).
In situ hybridisation
Antisense 72 kDa and 92 kDa was generated from the
pGEM3-72K and pGEM3-92K (kindly provided by British
Biotechnology, Oxford, UK) using the relevant RNA poly-
merase (Promega Biotech, Madison, USA). The negative
control was sense RNA generated from the same vector
linearised in the opposite direction. In vitro transcriptions
were performed using Promega Biotech transcription kits to
incorporate 35S-UTP (Amersham International SJ 1303).
Restriction enzymes were all obtained from Pharmacia.
In situ hybridisation was carried out on cryostat sections as
in Naylor et al., 1990.
Immunohistochemistry
A sheep polyclonal antibody to Mr 92 kDa collagenase was a
generous gift of Dr Gillian Murphy, Strangeways Labor-
atory, Cambridge. This antibody has been extensively charac-
terised (Murphy et al., 1989). Following blocking in normal
rabbit serum, the primary antibody was applied in a 1/200
dilution. The second layer was peroxidase conjugated rabbit
anti-goat (Dakopatts) which had been pre-absorbed in nor-
mal human serum. Sections were developed using 0.01%
H202/Diaminobenzidine-tetrachloride and counterstained
with Mayer's haemotoxylin. Parallel runs omitting the
primary antibody were included as a negative control in all
cases.
TPA-treated HT-1080
conditioned medium
RPMI-7951
conditioned medium
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Figure 1 Zymography of breast cancer tissue. Lane 1 = 12JLI RPMI 7951 supernatant showing 72 kDa type IV collagenase. Lane
2 = 12jld TPA stimulated HT-1080 supernatant showing 92 kDa type IV collagenase, 72 kDa type IV collagenase and its activated
forms (59/62 kDa doublet). Lanes 3-12 = breast cancer samples A-J.1128 B. DAVIES et al.
Results
Zymography
Type IV collagenase activity was assessed in 11 cases of
normal/benign breast disease and 32 cases of invasive ductal
carcinoma of varying grade, by measuring their gelatinolytic
activity in gel substrate analysis. For each tumour sample the
activities of 92 kDa and 72 kDa type IV collagenases were
calculated in arbitrary units per 10ytg of protein. The activity
of the 72 kDa type was resolved into its inactive proform
(72 kDa) and its active form (62 kDa). Conditioned media
from human tumour cell lines, which are known to contain
type IV collagenases, were used as standards as described in
the Methods.
Tables I and II show the levels of different species of type
IV collagenases in benign and malignant breast tissue of
varying tumour grade. Computer assisted image analysis was
used to quantify the results. To assess the reproducibility of
the quantification technique, sections were cut from different
portions from the same tumour and collagenase activity
assessed. Variation in collagenase activity between sections of
the same tumour was a mean of 11.3% in 18 determinations.
The 92 kDa form of type IV collagenase and its activation
products were present in three of 11 benign cases, three of
nine grade I tumours, four of 12 grade II tumours but in 11
of 11 grade III tumours (Table I). Mean levels of this form
were significantly higher in grade III tumours when com-
pared with the other cases (32.25 U ± 10.67 vs 5.19 U ± 1.98,
P<0.0001). Using this percentage of acrylamide gel we were
unable to accurately distinguish between 92 kDa procol-
lagenase and its activation product of Mr 81 kDa (Brown et
al., 1990).
Table II shows the levels of 72 kDa proform and the
activated 62 kDa collagenase in the breast biopsies. The
72 kDa enzyme was found in all benign and malignant tis-
sues examined. The 62 kDa active form was found in 10/11
normal/benign, 7/9 grade I, 12/12 grade II, and 11/11 grade
III tumours. When the levels of 72 kDa proenzyme and its
active 62 kDa form were considered together there was no
Table I Levels of 92 kDa collagenase in breast biopsies
Number ofpositive Mean 92 + 81 kDa activity
Pathology cases/total (U/JO[Lg protein ± S.E.)
Benign/ 3/11 6.58 3.4
normal
Malignant
grade I 3/9 1.34 0.8
grade II 4/12 6.80 4.27
grade III 11/11 32.29 10.67
Homogenates of tissue were applied to 11% acrylamide gels as
described in the Methods.
Levels of 92 kDa collagenase in grade III tumours vs levels in all
other tumour/benign specimens P<0.0001.
Table II Levels of 72kDa collagena
biopsi
difference between the benign and malignant cases
(30.05 U ± 4.84 vs 27.64 U ± 3.48, p = 0.55). When the inac-
tive (72 kDa) form was considered alone, there were
significantly higher levels in benign compared with malignant
disease (22.88 U ± 3.71 vs 14.04 U ± 1.89, P=0.03). The
mean level of the active (62 kDa) form was higher in malig-
nant compared with benign samples (13.57 U ± 1.94 vs
7.18 U ± 2.17), though this failed to reach standard levels of
significance (P = 0.06). When the amount of the active
(62 kDa) enzyme was considered as a proportion of the total
amount of the 72 + 62 kDa species present, the proportion in
malignant disease was significantly higher than that found in
benign/normal breast tissue (0.45 vs 0.20, P = 0.003).
Although the total amount of 72 + 62 kDa activity did not
differ significantly between tumours of different histological
grades, the proportion of the active form of the enzyme
correlated with tumour grade, test for trend (rank correla-
tion), P<0.0001 (Table II).
Figure I shows an example of zymograms from ten cases
of primary breast cancer (lanes A-J). All of these tumours
express the Mr 72kDa type IV procollagenase. These
activities ranged from 4.2 U (sample F) to 37.9 U (sample A).
Levels of the Mr 62 kDa enzyme varied between OU (sample
F) to 26.2 U (sample A). Considerable variation was
observed in the levels of the Mr 92/81 kDa enzyme (185.4 U
sample C to OU samples, D,E,F,G).
Localisation oftype IV collagenase expression
Further experiments were carried out to localise these
enzymes in the tumour tissue. Figure 2a shows the location
of the 92 kDa collagenase mRNA in a grade III ductal
carcinoma. mRNA expression was seen in collections ofelon-
gated spindle shaped cells lying within tumour stroma. These
cells were of fibroblast or macrophage morphology. The
signals were particularly strong in stroma adjacent to foci of
ductal carcinoma in situ. Protein expression was also
confirmed in adjacent sections using a polyclonal antibody to
the 92 kDa form of the enzyme. Distribution of protein was
shown to be similar to that of the mRNA (Figure 2b). As
well as stromal distribution within spindle shaped cells,
92 kDa mRNA and protein was also identified in putative
myoepithelial cells in some areas of ductal carcinoma in situ
adjacent to the invasive carcinoma (Figure 2c and d). Consis-
tent results were obtained in ten samples of malignant breast
disease.
Detection of mRNA for the 72 kDa enzyme by in situ
hybridisation was also carried out in seven cases. This
enzyme showed a similar pattern of expression to the 92 kDa
enzyme, being found predominantly in spindle shaped cells in
the stroma.
tse and its 62 kDa form in breast
Mean collagenase activity
(U/1O Ag protein) Ratio
Pathology No: 62kDa 72kDa 62+ 72 62/62 + 72
Benign/ 11 7.18 22.88 30.05 0.20
Normal
Malignant
grade I 9 14.69 17.58 32.27 0.33 test for
grade II 12 11.48 13.84 25.4 0.45 trend
grade III 11 14.93 11.36 26.29 0.55 P<0.0001
Homogenates of tissue were applied to 11% acrylamide gels as described
in the Methods. The 72 kDa proform was found in all tissues. The 62 kDa
active form was found in 10/11 normal/benign, 7/9 grade I, 12/12 grade II,
and 11/11 grade III samples.
Levels of 62 kDa benign vs malignant P = 0.06.
Levels of 72 kDa benign vs malignant P = 0.03.
Ratio of 62 to 62 + 72 kDa benign vs malignant P = 0.003.COLLAGENASES AND BREAST CANCER 1129
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Figure 2 Localisation of 92 kDa collagenases in malignant breast tissue. Adjacent sections showing in situ hybridisation to mRNA
a and protein b for the 92 kDa collagenase in stomal cells of a Grade 3 ductal carcinoma. Adjacent sections showing in situ
hybridisation to mRNA c and protein d for the 92 kDa collagenase in myoepithelial cells surrounding a grade 1 ductal carcinoma
in situ. T-tumour cells. Tcis-areas of carcinoma in situ. MY-myoepithelial cell. MA-cell of macrophage-like morphology.
Discussion
In this study increased production of 92 kDa type IV col-
lagenase was associated with increasing severity of grade of
human breast carcinomas. In situ hybridisation and
immunostaining showed that mRNA and protein for this
enzyme were expressed not by the tumour cells themselves
but by cells in the surrounding stroma. Some of the cells
expressing the 92 kDa enzyme were myoepithelial cells, other
cells present in the stroma also expressed the enzyme and
were probably macrophages or fibroblasts. Cells of the
mononuclear phagocyte lineage have been widely reported to
secrete 92 kDa type IV collagenase (Hibbs et al., 1987; Wel-
gus et al., 1990) and this activity is affected by, for example,
treatment with LPS or concanavalin A. The tissue location of
macrophages also affects the extent to which they express this
enzyme, but the precise control mechanisms and mediators
operating in vivo have not yet been elucidated. Expression of
the 72 kDa type IV collagenase by fibroblasts in vitro and in
vivo is well documented (Seltzer et al., 1981; Goldberg et al.,
1986; Ballin et al., 1988) but they do not secrete the 92 kDa
enzyme under normal conditions. However SV40 trans-
formed fibroblasts do secrete the 92 kDa enzyme (Wilhelm et
al., 1989) and we speculate that fibroblasts may be induced
to express this enzyme by tumour derived factors.
The control of type IV collagenase secretion by cytokines
and growth factors is poorly defined. TGF-P1 increases secre-
tion of both the 72 kDa and 92 kDa enzymes in tumour cells
and fibroblasts (Overall et al., 1989; Weinberg et al., 1990;
Welch et al., 1990) and TNF-a has been reported to increase
the secretion of the 92 kDa enzyme, but not the 72 kDa type,
by tumour cells (Brenner et al., 1989; Okada et al., 1990).
Interestingly, we have found that a minority (<0.1%) of
predominantly stromal cells in a series of 80 breast cancer
biopsies express mRNA for TNF and produce immunoreac-
tive TNF protein. Phenotyping of cells in sequential sections
suggests that CD68 positive activated macrophages produce
this cytokine. The level of TNF expression increased with
severity of histological grade (Miles et al., manuscript in
preparation).
Seventy-two kDa type IV collagenase has previously been
reported to be localised in tumour epithelial cells and in
myoepithelial cells in normal breast and tumour
(Monteagudo et al., 1990). We found no correlation between
disease severity and levels of expression of 72 kDa type IV
collagenase. However when the proportion of activated to
total 72 kDa type IV collagenase was compared to tumour
grade, there was a clear correlation with ratio increasing in
proportion to grade. Immunohistochemical methods would
not have been able to detect this relationship. Seventy-
two kDa type IV collagenase, in common with other matrix
metalloproteinases, is secreted in inactive pro-form and
activation occurs by proteolytic removal of an N-terminal
sequence (Stetler-Stevenson et al., 1989). This can be
achieved in vitro by treatment with trypsin or by autop-
roteolysis following treatment with organomercurial com-
pounds. How this proteolytic activation occurs in vivo and
how it is controlled is unclear. However, exogenously added
72 kDa enzyme is activated by concanavalin A treated
fibroblasts and this activation is blocked by inhibitors of
c
d
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protein synthesis. Activation is also blocked by inhibitors of
matrix metalloproteinases (Ward et al., 1991). We need to
understand further the activation process of the 72 kDa
enzyme in order to explain our finding that this occurs more
readily in tumours of higher histological grade. Investigations
of the microenvironment of breast tumours, particularly in
terms of endogenous cytokine/growth factor production, are
also required to understand control of type IV collagenase
expression.
As the collagenases localise to the stroma, changes in levels
with tumour grade may be related to differences in stromal
development. This explanation is, however, unlikely for two
reasons. First, we find not only a change in level of 92 kDa
collagenase, but also a higher proportion of grade III
tumours expressing the enzyme; and second, we find a
significant increase in the ratio of active to total 72 kDa
enzyme with increasing tumour grade although the total
amount of enzyme is not increased.
The relationship between type IV collagenase expression
and tumour grade may partly explain the relationship
between tumour grade and behaviour since basement mem-
brane degradation is a prerequisite for invasion and metas-
tasis. Inhibitors of Type IV collagenase activity could,
therefore, find a role in the management of breast cancer and
clinical studies are indicated.
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